Key Drivers
- Gross Margin Strength
- Thin Cash Conversion
- Heavy Intangibles
AIAI Summary
LIVN has shifted from a turnaround to an evidence-backed growth story with stronger revenue, guidance, and clinical data, but the investment case still hinges on proving durable free cash flow and flawless execution—especially on aura6000/FDA—before the market can fully trust the upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross Margin Strength
- •Thin Cash Conversion
- •Heavy Intangibles
LIVN shows strong gross margins and a Q1 profit rebound, but weak recent cash generation, moderate leverage, and a still-not-cheap valuation keep the outlook mixed.
Price Behavior
Key Price Behavior Insights:
- •Uptrend intact
- •Breakout confirmed
- •Pullback risk
LIVN remains in a constructive short-term uptrend with higher highs/lows and a breakout above $79.95-$81.05, but the stock is extended after a fast run to $83.62, so holding above $78.50 is key.
Fast climb from $71.33 to $83.62 with uneven mid-to-late
Sentiment & News
Key News Insights:
- •Leadership refresh
- •Promising OSA data
- •Earnings ahead
LivaNova is reinforcing governance and investor communication while its sleep-apnea program reports encouraging PolySync data ahead of its upcoming Q2 earnings call.
The combination of board/management updates and positive clinical results may help sustain investor interest into the next earnings release
Similar Companies in Healthcare
Other companies in the same sector with AI ratings